by Lee Seonae
Published 09 Dec.2021 11:18(KST)
[Asia Economy Reporter Lee Seon-ae] GC Cell announced on the 9th that it has acquired a patent for a cultivation method of umbilical cord blood-derived natural killer cells using genetically modified T cells.
The patent relates to a method for efficiently proliferating natural killer cells using genetically modified CD4+ T cells, which express at least one gene selected from a group consisting of 4-1BBL gene, mbIL-21 gene, OX40L gene, and mTNF-α gene, as feeder cells.
The company explained, “By using genetically modified T cells as feeder cells, it is possible to mass-culture high-purity and highly active natural killer cells, which offers advantages for the commercialization of cell therapy products.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.